India Not Target Of U.S. FDA Witch-Hunt, Analysts Say
This article was originally published in PharmAsia News
Executive Summary
India drug makers should not feel they are being singled out for extra scrutiny by the U.S. FDA, analysts say, the nation just has the second largest number of production plants approved by the agency.
India drug makers should not feel they are being singled out for extra scrutiny by the U.S. FDA, analysts say, the nation just has the second largest number of production plants approved by the agency. A drug maker blamed an increase in FDA scrutiny after Ranbaxy Laboratories agreed to a $500 million fine for violations at some of its plants. But most analysts said the agency is not necessarily on a witch-hunt, that it reviews companies around the world and issues alerts to anyone it finds in violation. (Click here for more
)
"Indian Pharma Companies Under Global Scrutiny, No Witch-Hunt, Say Experts" - Hindustan Times (India) (7/25/2013)